Abstract
Microenvironmental stimuli affect EZH2 expression and function in CLL.
Combined B-cell signaling and EZH2 inhibition showed synergistic effects on primary CLL cells.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenine / analogs & derivatives
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology
-
Apoptosis / drug effects
-
B-Lymphocytes / drug effects
-
B-Lymphocytes / metabolism
-
Bridged Bicyclo Compounds, Heterocyclic / pharmacology
-
Down-Regulation / drug effects
-
Drug Synergism
-
Enhancer of Zeste Homolog 2 Protein / antagonists & inhibitors*
-
Enhancer of Zeste Homolog 2 Protein / drug effects
-
Enhancer of Zeste Homolog 2 Protein / metabolism
-
Enzyme Inhibitors / pharmacology
-
Histones / drug effects
-
Humans
-
Indazoles / pharmacology
-
Indoles / pharmacology
-
Leukemia, Lymphocytic, Chronic, B-Cell / blood
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
-
Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
-
Piperidines
-
Purines / pharmacology
-
Pyrazoles / pharmacology
-
Pyridones / pharmacology
-
Pyrimidines / pharmacology
-
Quinazolinones / pharmacology
-
Signal Transduction / drug effects*
-
Sulfonamides / pharmacology
-
Tumor Microenvironment / drug effects
Substances
-
Antineoplastic Agents
-
Bridged Bicyclo Compounds, Heterocyclic
-
Enzyme Inhibitors
-
GSK-2816126
-
GSK343
-
Histones
-
Indazoles
-
Indoles
-
Piperidines
-
Purines
-
Pyrazoles
-
Pyridones
-
Pyrimidines
-
Quinazolinones
-
Sulfonamides
-
ibrutinib
-
EZH2 protein, human
-
Enhancer of Zeste Homolog 2 Protein
-
Adenine
-
venetoclax
-
idelalisib